Washington, Sept 27: Experimental drug axitinib has been found to have potential to bring respite to patients with advanced kidney cancer, whose options run out after their tumour fails to respond to the cutting edge therapy.

The study, led by Dr Brian I. Rini an associate professor of medicine at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, USA, and a paid member of the Pfizer scientific advisory board, demonstrated that the drug shrank tumours, and delayed the disease’s progression.

Washington, September 27 : People who drink can significantly reduce their likelihood of suffering from cancers of head and neck by quitting alcohol consumption, a research at the Centre for Addiction and Mental Health (CAMH) has suggested.

Principal Investigator Dr. Jurgen Rehm says that his study has shown an association between alcohol consumption and an increased risk for cancer of the oesophagus, larynx and oral cavity.

Washington, September 27 : The symptoms of the brain development disorder autism can improve with age, says an assistant professor of social work at Washington University in St. Louis.

The new finding is based on a study whose first author Paul T. Shattuck worked on it as a graduate student and post-doctoral fellow at the University of Wisconsin-Madison's Waisman Center.

London, September 27 : Danish researchers have advised women not to take any strenuous exercise in the early stages of pregnancy because it may triple the risk of miscarriage.

Researchers at the University of Southern Denmark quizzed more than 90,000 women on their exercise regime, and linked their answers to the outcome of their pregnancies.

Washington, Sept 27 : Though cancer patients and health specialists believe that acupuncture offers relief from radiotherapy-induced nausea, a new study has revealed that it does not.

Washington, Sept 27: According to a new study a new molecular target in blood clot formation has been found which may help to reduce clotting without any excessive bleeding.

unveils a new molecular target for anti-platelet drugs, which may avoid the dangerous side-effects of the current drugs."

The study, led by Shafi Kuchay and Dr. Athar Chishti, was made at the University of Illinois at Chicago College of Medicine.